Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial
暂无分享,去创建一个
G. Remuzzi | B. Ene-Iordache | F. Gaspari | P. Ruggenenti | N. Rubis | N. Motterlini | A. Perna | P. Cravedi | R. Trevisan | G. Gherardi | Aneliya Parvanova Ilieva | I. Iliev | A. Bossi | A. Fassi | C. Chiurchiu | Giulia Gherardi
[1] T. Uzu,et al. Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes , 2007, Diabetes.
[2] G. Remuzzi,et al. Time to abandon microalbuminuria? , 2006, Kidney international.
[3] E. Montanya,et al. Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. , 2005, Diabetes research and clinical practice.
[4] K. Narayan,et al. Trends in cardiovascular complications of diabetes. , 2005, JAMA.
[5] M. Mauer,et al. Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.
[6] M. Nieminen,et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.
[7] G. Bakris,et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. , 2004, Kidney international.
[8] A. Perna. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. , 2003, Controlled clinical trials.
[9] G. Viberti,et al. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.
[10] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[11] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[12] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[13] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[14] G. Bakris,et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. , 1998, Kidney international.
[15] G. Remuzzi,et al. The diagnosis of renal involvement in non‐insulin-dependent diabetes mellitus , 1997, Current opinion in nephrology and hypertension.
[16] S. Leurgans,et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. , 1996, Kidney international.
[17] H. Parving,et al. Prevention of diabetic renal disease with special reference to microalbuminuria , 1995, The Lancet.
[18] W. D. Ray. 4. Modelling Survival Data in Medical Research , 1995 .
[19] M. Lishner,et al. Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients , 1993, Annals of Internal Medicine.
[20] H. Keen,et al. MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUS , 1982, The Lancet.
[21] M. Abbal,et al. FACTOR-VIII COMPLEX AND ENDOTHELIAL DAMAGE , 1975, The Lancet.